Novel Cardiovascular Drug Delivery Devices Market, Distribution by Type of Drug Eluted (Sirolimus, Paclitaxel, Everolimus, Zotarolimus and Others), Stent Material (Platinum Chromium, Cobalt Chromium, Stainless Steel and Others), and Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    April 2022

  • Pages
    254

  • View Count
    2510

Example Insights

Novel-Cardiovascular-Drug-Delivery-Devices-Market-Context-thumb Novel-Cardiovascular-Drug-Delivery-Devices-Market-List-of-Companies-thumb Novel-Cardiovascular-Drug-Delivery-Devices-Market-Grid-Representation-thumb
Novel-Cardiovascular-Drug-Delivery-Devices-Market-Company-Competitiveness-Analysis-thumb Novel-Cardiovascular-Drug-Delivery-Devices-Market-Patent-Analysis-thumb Novel-Cardiovascular-Drug-Delivery-Devices-Market-Distribution-by-Type-of-Therapy-thumb
Novel-Cardiovascular-Drug-Delivery-Devices-Market-Distribution-by-Region-thumb Novel-Cardiovascular-Drug-Delivery-Devices-Market-Forecast-thumb  

 

Overview

Cardiovascular diseases (CVD) are reported to be one of the leading causes of deaths across the globe, surpassing conditions, such as cancer and respiratory disorders.  According to the WHO, around one third of the annual global deaths (an estimated 18 million) can be attributed to cardiac disorders.  Specifically, coronary artery disease (CAD) is the most common form of cardiovascular disorder; around 11 million deaths were linked to this indication in 2020.  It is worth mentioning that, in 2020 (post the onset of the pandemic), a more than 3% increase in the deaths related to heart diseases was reported. Further, according to the Centers for Disease Control and Prevention, the financial burden (in terms of annual medical costs and loss of productivity) associated with cardio vascular diseases is expected to be surpass USD 1,000 billion, in 2030.  In order to prevent the critical effects of vessel narrowing and plaque buildup in arteries, various coronary interventional devices are being used; cardiovascular stents have emerged as one of the most preferred solutions to mitigate the aforementioned concerns. Traditionally, bare-metal stent (BMS) was used extensively to open the blocked passages and restore adequate blood flow to the heart. In recent years, a shift in preference has been observed towards the use of drug-eluting stent (DES), which are coated with a polymer carrying an antiproliferative drug. Such stents have been demonstrated to reduce / prevent in-stent restenosis (re-narrowing of the arteries previously opened using angioplasty), which was a major complication associated with the use of bare-metal stents.  Drug eluting stents are considered to be revolutionary in the interventional cardiology domain, as they enable improved revascularization rates and reduced risk of thrombosis.

Presently, over 90 cardiovascular drug eluting stents are being offered by around 40 players located across the globe. Majority of such devices employ the use of metals, such as platinum chromium and stainless steel. Further, the patents focused on cardiovascular drug eluting stents and associated technologies have been filed / granted at a CAGR of 13%, in the past two decades. In this context, it is important to note that, over the past few years, there have been significant innovations in cardiovascular therapeutics domain, in terms of development of advanced bioresorbable stents, drug combinations, polymer and nanomaterial coatings, to further increase the safety and efficacy of these treatment options. For instance, recently, an implantable biocompatible stent containing miniaturized ultrasonic transducers have been proposed by a group of researchers, which can be used for real-time monitoring of restenosis in the patients. Moreover, recent advancements related to the use of augmented reality and deep learning can enable the development of patient-specific stents, paving the way for personalized-treatment for patients suffering from cardiovascular disorders. Given the ongoing pace of innovation in this field, adoption of cutting-edge technologies by device developers, the ever-increasing incidence of heart diseases and the rise in demand for associated treatments, we believe that the cardiovascular drug eluting stent market is likely to evolve at a rapid pace, over the coming years.

Scope of the Report

The “Novel Cardiovascular Drug Delivery Devices Market, Distribution by Type of Drug Eluted (Sirolimus, Paclitaxel, Everolimus, Zotarolimus and Others), Stent Material (Platinum Chromium, Cobalt Chromium, Stainless Steel and Others) and Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of cardiovascular drug eluting stents in the healthcare domain, till 2035. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this market space. Amongst other elements, the report includes:

  • A detailed overview of the current market landscape of the players engaged in developing / manufacturing cardiovascular drug eluting stents, including information on their respective year of establishment, company size (in terms of number of employees), number of products offered and location of headquarters. Further, it provides a detailed assessment of the overall landscape of over 90 cardiovascular drug eluting stents, based on several relevant parameters, such as type of eluted drug, type of stent material, post dilatation limit, stent length, stent diameter, nominal pressure, rated burst pressure and administered drug concentration.
  • An in-depth analysis, highlighting the contemporary market trends, using five schematic representations, including a heat map representation (based on type of drug eluted and administered drug concentration), a stacked bar chart representation (by the type of drug eluted and stent material), a tree map representation (based on  maximum stent length and maximum stent diameter), a 4D bubble chart representation comparing the players engaged in cardiovascular drug eluting stents domain (based on several relevant parameters (such as year of establishment, company size, number of products offered and location of headquarters)) and a grid representation (based on company size, number of products offered, maximum stent length, maximum stent diameter and location of headquarters).
  • An insightful company competitiveness analysis of cardiovascular drug eluting stent developers, taking into consideration various relevant parameters, such as year of experience and portfolio strength (in terms of number of products offered, stent material, maximum stent length, maximum stent diameter, maximum nominal pressure, maximum rated burst pressure, and lowest strut thickness).
  • Elaborate profiles of various prominent players that are currently engaged in developing / manufacturing drug eluting stents employed for the treatment of cardiovascular disorders, featuring a brief overview of the company (including information on its year of establishment, number of employees, location of headquarters, key members of the executive team and cardiovascular drug delivery device portfolio), recent developments and an informed future outlook.
  • An in-depth analysis of the various patents that have been filed / granted related to cardiovascular drug eluting stents, based on various parameters, such as patent type, publication year, geographical location, CPC symbol, emerging focus areas, type of applicant and leading industry / non-industry players (in terms of the size of intellectual property portfolio). Further, it features a three-dimensional bubble analysis (based on patent citation count, publication year, extended geographical reach), patent benchmarking analysis and a detailed patent valuation analysis.
  • An insightful case study focused on novel cardiovascular therapeutics (such as gene therapy, next generation complements, oral proteins and peptides, regulatory t-cell (tregs) therapies and subcutaneous biologics) and novel cardiovascular-based services / solutions (such as biopharmaceutical contract research offerings, digital therapeutics and precision medicine software). It also features a list of developers, along with details on their year of establishment, company size and location of headquarters. 
  • An elaborate analysis in order to estimate the current and future demand for cardiovascular drug eluting stents, based on several relevant parameters, such as type of drug eluted (sirolimus, paclitaxel, everolimus, zotarolimus and others), type of stent material (platinum chromium, cobalt chromium, stainless steel and others) and key geographical regions (North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World) for the period 2022-2035. Kindly note that input parameters considered for this analysis include number of patients suffering from cardiovascular disorders that can be treated using cardiovascular drug eluting stents and average price of such stents across various geographies.

One of the key objectives of the report was to estimate the existing market size and future opportunities associated with cardiovascular drug eluting stents over the next decade. Based on several parameters, such as annual cases reported for cardiovascular disorders, percutaneous coronary interventions performed (in terms of number of patients) to treat such disorders, and average price for associated drug eluting stents across various geographical regions, we have provided an informed estimate on the evolution of the market for the period 2022-2035. The report also features the likely distribution of the current and forecasted opportunity related to Novel Cardiovascular Drug Delivery Devices Market across type of drug eluted (sirolimus, paclitaxel, everolimus, zotarolimus and others), type of stent material (platinum chromium, cobalt chromium, stainless steel and others) and key geographical regions (North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World). In order to account for future uncertainties and add robustness to our forecast model, we have provided three forecast scenarios, portraying the conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with several industry stakeholders.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading players offering cardiovascular drug eluting stents?
  • Which type of drug eluting stent is most commonly offered by developers engaged in this market space?
  • What is the relative competitiveness of different players engaged in the development / manufacturing of cardiovascular drug eluting stents?
  • How has the patent landscape in this domain evolved over the last two decades?
  • What is the present and likely future demand for cardiovascular drug eluting stents in the overall healthcare sector?
  • What are the anticipated future trends related to novel cardiovascular drug delivery devices market?
  • How is the current and future opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of novel cardiovascular drug delivery devices market and its likely evolution in the short to mid and long term.  

Chapter 3 is an introductory chapter that highlights important concepts related to cardiovascular drug eluting stents. It also features information on various types of cardiovascular drug delivery devices, key indications targeted by such devices and potential risks associated with their use. This chapter further features details about the recent advancements that have been made related to cardiovascular drug delivery devices.

Chapter 4 provides a detailed overview of the current market landscape of players engaged in the development of cardiovascular drug eluting stents, along with information on their year of establishment, company size, number of products offered and location of headquarters. Further, it highlights a detailed assessment of the overall market landscape of over 90 cardiovascular drug eluting stents, based on several relevant parameters, such as type of drug eluted (sirolimus, paclitaxel, everolimus, zotarolimus and others), type of stent material (platinum chromium, cobalt chromium, nitinol, stainless steel and others), post dilatation limit, stent length, stent diameter, nominal pressure, rated burst pressure and administered drug concentration.

Chapter 5 features an analysis, highlighting the contemporary market trends through five different schematic representations, including a heat map representation based on eluted drug and administered drug concentration, a stacked bar chart representation based on the type of drug eluted and stent material, a tree map representation based on  maximum stent length and maximum stent diameter, a 4D bubble chart representation comparing the players engaged in cardiovascular drug eluting stents domain, based on several relevant parameters (such as year of establishment, company size, number of products offered and region), and a grid representation based on company size, number of products offered, maximum stent length, maximum stent diameter and location of headquarters.

Chapter 6 presents an insightful competitiveness analysis of players involved in the production / development of cardiovascular drug eluting stents, based on several relevant parameters, such as years of experience, portfolio strength (in terms of number of products offered, stent material, maximum stent length, maximum stent diameter, maximum nominal pressure, maximum rated burst pressure, and lowest strut thickness)

Chapter 7 features elaborate profiles of various prominent players that are currently engaged in providing cardiovascular drug eluting stents. Each company profile features a brief overview of the company (including information on its year of establishment, number of employees, location of headquarters, key members of the executive team and cardiovascular drug delivery device portfolio), recent developments and an informed future outlook.

Chapter 8 provides an insightful analysis on patent focused on cardiovascular drug eluting stents. The chapter provides an overview on the filed / granted patents related to cardiovascular drug eluting stents. For this analysis, we looked at the patents that have been published by various players, till February 2022. The analysis highlights key details and trends associated with these patents, including patent type, publication year, geographical location, assigned CPC symbol, emerging focus area, type of applicant and leading industry / academic players (in terms of size of intellectual property portfolio). It features a three-dimensional bubble analysis (based on patent citation count, publication year, extended geographical reach). It also includes a patent benchmarking analysis and a detailed valuation analysis.

Chapter 9 presents a case study focused on novel cardiovascular therapeutics (such as gene therapy, next generation complements, oral proteins and peptides, regulatory t-cell (tregs) therapies and subcutaneous biologics) and novel cardiovascular-based services / solutions (such as biopharmaceutical contract research offerings, digital therapeutics and precision medicine software), featuring a list of such players with details on their year of establishment, company size and location of headquarters. A detailed assessment of the overall market landscape of novel cardiovascular therapeutics is provided, based on the phase of development, route of administration, type of molecule, and mechanism of action. Further, an elaborate analysis of the overall market landscape of novel cardiovascular-based services / solutions is provided, based on several relevant parameters, such as types of services, purpose of software and end users.

Chapter 10 includes an in-depth analysis in order to estimate the current and future demand for cardiovascular drug eluting stents, based on several relevant parameters, such as type of drug eluted (sirolimus, paclitaxel, everolimus, zotarolimus and others), type of stent material (platinum chromium, cobalt chromium, stainless steel and others) and key geographical regions (North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World) for the period 2022-2035. Kindly note that the input parameters considered for this analysis include the number of patients suffering from cardiovascular disorders that can be treated using drug eluting stents and the average price of such stents across various geographies.

Chapter 11 features a comprehensive market forecast analysis, highlighting the likely growth of the novel cardiovascular drug delivery devices market, for the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across various segments, such as type of drug eluted (sirolimus, paclitaxel, everolimus, zotarolimus and others), type of stent material (platinum chromium, cobalt chromium, stainless steel and others) and key geographical regions (North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World).

Chapter 12 summarizes the overall report, wherein all the key facts and figures have been mentioned. Further, the chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the novel cardiovascular drug delivery devices market.

Chapter 13 is a collection of interview transcripts of discussions held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with several stakeholders.

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Content

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1 Chapter Overview
3.2. Overview of Cardiovascular Drug Delivery Devices
3.2.1. Types of Cardiovascular Drug Delivery Devices
3.2.1.1. Drug Eluting Stents (DES)
3.2.1.2. Drug Eluting Balloons (DEB)

3.3. Key Indications Targeted by Cardiovascular Drug Delivery Devices
3.3.1. Atherosclerosis
3.3.2. Heart Failure 
3.3.3. In-Stent Restenosis

3.4. Potential Risks Associated with Drug Eluting Stents and Balloons
3.5. Recent Advancements Related to Cardiovascular Drug Delivery Devices 

3.6. Concluding Remarks

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Novel Cardiovascular Drug Delivery Devices: Overall Market Landscape
4.2.1. Analysis by Type of Drug Eluted
4.2.2. Analysis by Stent Material
4.2.3. Analysis by Maximum Post Dilatation Limit
4.2.4. Analysis by Maximum and Minimum Stent Length
4.2.5. Analysis by Maximum and Minimum Stent Diameter
4.2.6. Analysis by Maximum Nominal Pressure
4.2.7. Analysis by Maximum Rated Burst Pressure
4.2.8. Analysis by Administered Drug Concentration
4.2.9. Analysis by Minimum Strut Thickness

4.3. Novel Cardiovascular Drug Delivery Devices: Developers Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Leading Players: Analysis by Number of Products

5. KEY INSIGHTS
5.1. Chapter Overview
5.2. Analysis by Eluted Drug and Administered Drug Concentration (Heat Map)
5.3. Analysis by Eluted Drug and Stent Material (Stacked Bar Chart)
5.4. Analysis by Maximum Stent Length and Maximum Stent Diameter (Tree Map)
5.5. Analysis by Year of Establishment, Company Size, Number of Products Offered and Region (4D Bubble Chart)
5.6. Analysis by Company Size, Region, Number of Products Offered, Maximum Stent Length and Maximum Stent Diameter (Grid Representation)

6. COMPANY COMPETITIVENESS
6.1. Chapter Overview
6.2. Key Assumptions and Parameters
6.3. Methodology
6.3.1. Company Competitiveness Analysis: Small Companies
6.3.2. Company Competitiveness Analysis: Mid-sized Companies
6.3.3. Company Competitiveness Analysis: Large Companies
6.3.4. Company Competitiveness Analysis: Very Large Companies

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Alvimedica
7.2.1. Company Overview
7.2.2. Novel Cardiovascular Drug Delivery Device Portfolio
7.2.3. Recent Developments and Future Outlook

7.3. B. Braun
7.3.1. Company Overview
7.3.2. Novel Cardiovascular Drug Delivery Device Portfolio 
7.3.3. Recent Developments and Future Outlook

7.4. Boston Scientific
7.4.1. Company Overview
7.4.2. Novel Cardiovascular Drug Delivery Device Portfolio
7.4.3. Recent Developments and Future Outlook

7.5 Cook Medical
7.5.1. Company Overview
7.5.2. Novel Cardiovascular Drug Delivery Device Portfolio 
7.5.3. Recent Developments and Future Outlook 

7.6. Eurocor Scientific
7.6.1. Company Overview
7.6.2. Novel Cardiovascular Drug Delivery Device Portfolio 
7.6.3. Recent Developments and Future Outlook

7.7. Lepu Medical
7.7.1. Company Overview
7.7.2. Novel Cardiovascular Drug Delivery Device Portfolio
7.7.3. Recent Developments and Future Outlook

7.8. Medtronic
7.8.1. Company Overview
7.8.2. Novel Cardiovascular Drug Delivery Device Portfolio
7.8.3. Recent Developments and Future Outlook 

7.9. Meril
7.9.1. Company Overview
7.9.2. Novel Cardiovascular Drug Delivery Device Portfolio
7.9.3. Recent Developments and Future Outlook

7.10. Relisys
7.10.1. Company Overview
7.10.2. Novel Cardiovascular Drug Delivery Device Portfolio
7.10.3. Recent Developments and Future Outlook

7.11. Sahajanand Medical Technologies
7.11.1. Company Overview
7.11.2. Novel Cardiovascular Drug Delivery Device Portfolio 
7.11.3. Recent Developments and Future Outlook

8. PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Novel Cardiovascular Drug Delivery Devices: Patent Analysis
8.3.1. Analysis by Type of Patent
8.3.2. Analysis by Publication Year
8.3.3. Analysis of Granted Patents by Publication Year
8.3.4. Analysis by Filed Patent by Publication Year
8.3.5. Analysis by Patent Publication Year and Type of Player
8.3.6. Analysis by Issuing Authority
8.3.7. Analysis by Patent Focus
8.3.8. Analysis by Patent Age
8.3.9. Analysis by CPC Symbols
8.3.10. Leading Players: Analysis by Number of Patents
8.3.11. Leading Inventors: Analysis by Number of Patents

8.4. Novel Cardiovascular Drug Delivery Devices: Patent Benchmarking Analysis
8.4.1. Analysis by Patent Characteristics

8.5. Novel Cardiovascular Drug Delivery Devices: Patent Valuation Analysis 

9. CASE STUDY: NOVEL CARDIOVASCULAR THERAPEUTICS AND SERVICES / SOLUTIONS
9.1. Chapter Overview
9.2. Novel Cardiovascular Therapeutics: Overall Market Landscape
9.2.1. Novel Cardiovascular Therapeutics Developers: Distribution by Year of Establishment
9.2.2. Novel Cardiovascular Therapeutics Developers: Distribution by Company Size
9.2.3. Novel Cardiovascular Therapeutics Developers: Distribution by Location of Headquarters
9.2.4. Novel Cardiovascular Therapeutics Developers: Distribution by Type of Therapy
9.2.5. Novel Cardiovascular Therapeutics Developers: Distribution by Phase of Development
9.2.6. Novel Cardiovascular Therapeutics: Gene Therapy
9.2.7. Novel Cardiovascular Therapeutics: Next Generation Complement Therapeutics
9.2.8. Novel Cardiovascular Therapeutics: Oral Proteins and Peptides Therapies
9.2.9. Novel Cardiovascular Therapeutics: Regulatory T-cell (Tregs) Therapies
9.2.10. Novel Cardiovascular Therapeutics: Subcutaneous Biologics

9.3. Novel Cardiovascular-based Services / Solutions: Overall Market Landscape
9.3.1. Novel Cardiovascular-based Service Providers: Distribution by Year of Establishment

9.3.2. Novel Cardiovascular-based Service Providers: Distribution by Company Size
9.3.3. Novel Cardiovascular-based Service Providers: Distribution by Location of Headquarters

9.3.4. Novel Cardiovascular-based Service Providers: Distribution by Type of Service
9.3.5. Novel Cardiovascular-based Services: Biopharmaceutical Contract Research Services
9.3.6. Novel Cardiovascular-based Solutions: Digital Therapeutics Solutions
9.3.7. Novel Cardiovascular-based Solutions: Precision Medicine Software

10. DEMAND ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Methodology

10.3. Global Demand for Novel Cardiovascular Drug Delivery Devices, 2022-2035
10.3.1. Analysis by Type of Drug Eluted
10.3.1.1. Global Demand for Sirolimus Eluting Stents
10.3.1.2. Global Demand for Paclitaxel Eluting Stents
10.3.1.3. Global Demand for Everolimus Eluting Stents
10.3.1.4. Global Demand for Zotarolimus Eluting Stents
10.3.1.5. Global Demand for Other Drug Eluting Stents

10.3.2. Analysis by Stent Material
10.3.2.1. Global Demand for Platinum Chromium Stents
10.3.2.2. Global Demand for Cobalt Alloy Stents
10.3.2.3. Global Demand for Stainless Steel Stents
10.3.2.4. Global Demand for Stents Based on Other Materials

10.3.3. Analysis by Geography 
10.3.3.1. Demand for Novel Cardiovascular Drug Delivery Devices in North America
10.3.3.1.1. Demand for Novel Cardiovascular Drug Delivery Devices in the US
10.3.3.1.2. Demand for Novel Cardiovascular Drug Delivery Devices in Canada

10.3.3.2. Demand for Novel Cardiovascular Drug Delivery Devices in Europe
10.3.3.2.1. Demand for Novel Cardiovascular Drug Delivery Devices in France
10.3.3.2.2. Demand for Novel Cardiovascular Drug Delivery Devices in Germany
10.3.3.2.3. Demand for Novel Cardiovascular Drug Delivery Devices in Italy
10.3.3.2.4. Demand for Novel Cardiovascular Drug Delivery Devices in the Netherlands
10.3.3.2.5. Demand for Novel Cardiovascular Drug Delivery Devices in Spain
10.3.3.2.6. Demand for Novel Cardiovascular Drug Delivery Devices in the UK

10.3.3.3. Demand for Novel Cardiovascular Drug Delivery Devices in Asia
10.3.3.3.1. Demand for Novel Cardiovascular Drug Delivery Devices in China
10.3.3.3.2. Demand for Novel Cardiovascular Drug Delivery Devices in India
10.3.3.3.3. Demand for Novel Cardiovascular Drug Delivery Devices in Japan
10.3.3.3.4. Demand for Novel Cardiovascular Drug Delivery Devices in South Korea

10.3.3.4. Demand for Novel Cardiovascular Drug Delivery Devices in Middle East and North Africa
10.3.3.4.1. Demand for Novel Cardiovascular Drug Delivery Devices in Israel
10.3.3.4.2. Demand for Novel Cardiovascular Drug Delivery Devices in Turkey

10.3.3.5. Demand for Novel Cardiovascular Drug Delivery Devices in Latin America
10.3.3.5.1. Demand for Novel Cardiovascular Drug Delivery Devices in Brazil

10.3.3.6. Demand for Novel Cardiovascular Drug Delivery Devices in Rest of the World
10.3.3.6.1. Demand for Novel Cardiovascular Drug Delivery Devices in Australia
10.3.3.6.2. Demand for Novel Cardiovascular Drug Delivery Devices in New Zealand

11. MARKET FORECAST
11.1. Chapter Overview
11.2. Key Assumptions and Methodology

11.3. Global Novel Cardiovascular Drug Delivery Devices Market, 2022-2035
11.3.1. Analysis by Type of Drug Eluted
11.3.1.1. Global Sirolimus Eluting Stents Market
11.3.1.2. Global Paclitaxel Eluting Stents Market
11.3.1.3. Global Everolimus Eluting Stents Market
11.3.1.4. Global Zotarolimus Eluting Stents Market
11.3.1.5. Global Other Drug Eluting Stents Market

11.3.2. Analysis by Stent Material
11.3.2.1. Global Platinum Chromium Stents Market
11.3.2.2. Global Cobalt Alloy Stents Market
11.3.2.3. Global Stainless Steel Stents Market
11.3.2.4. Global Market for Stents Based on Other Materials

11.3.3. Analysis by Geography 
11.3.3.1. Novel Cardiovascular Drug Delivery Devices Market in North America
11.3.3.1.1. Novel Cardiovascular Drug Delivery Devices Market in the US
11.3.3.1.2. Novel Cardiovascular Drug Delivery Devices Market in Canada

11.3.3.2. Novel Cardiovascular Drug Delivery Devices Market in Europe
11.3.3.2.1. Novel Cardiovascular Drug Delivery Devices Market in France
11.3.3.2.2. Novel Cardiovascular Drug Delivery Devices Market in Germany
11.3.3.2.3. Novel Cardiovascular Drug Delivery Devices Market in Italy
11.3.3.2.4. Novel Cardiovascular Drug Delivery Devices Market in the Netherlands
11.3.3.2.5. Novel Cardiovascular Drug Delivery Devices Market in Spain
11.3.3.2.6. Novel Cardiovascular Drug Delivery Devices Market in the UK

11.3.3.3. Novel Cardiovascular Drug Delivery Devices Market in Asia
11.3.3.3.1. Novel Cardiovascular Drug Delivery Devices Market in China
11.3.3.3.2. Novel Cardiovascular Drug Delivery Devices Market in India
11.3.3.3.3. Novel Cardiovascular Drug Delivery Devices Market in Japan
11.3.3.3.4. Novel Cardiovascular Drug Delivery Devices Market in South Korea

11.3.3.4. Novel Cardiovascular Drug Delivery Devices Market in Middle East and North Africa
11.3.3.4.1. Novel Cardiovascular Drug Delivery Devices Market in Israel
11.3.3.4.2. Novel Cardiovascular Drug Delivery Devices Market in Turkey

11.3.3.5. Novel Cardiovascular Drug Delivery Devices Market in Latin America
11.3.3.5.1. Novel Cardiovascular Drug Delivery Devices Market in Brazil

11.3.3.6. Novel Cardiovascular Drug Delivery Devices Market in Rest of the World
11.3.3.6.1. Novel Cardiovascular Drug Delivery Devices Market in Australia
11.3.3.6.2. Novel Cardiovascular Drug Delivery Devices Market in New Zealand

12. CONCLUSION

13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Scitech Medical
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Luciano Curado, Chief Technology Officer

13.3. Translumina
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Harish Rawat, Production Executive

14. APPENDIX I: TABULATED DATA

15. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Key Indications Targeted by Cardiovascular Drug Delivery Devices
Figure 3.2 Recent Advancements Related to Cardiovascular Drug Delivery Devices Domain
Figure 3.3 Evolution of Interventional Cardiology Devices
Figure 4.1 Cardiovascular Drug Eluting Stents: Distribution by Type of Drug Eluted
Figure 4.2 Cardiovascular Drug Eluting Stents: Distribution by Stent Material
Figure 4.3 Cardiovascular Drug Eluting Stents: Distribution by Maximum Post Dilatation Limit
Figure 4.4 Cardiovascular Drug Eluting Stents: Distribution by Maximum Stent Length
Figure 4.5 Cardiovascular Drug Eluting Stents: Distribution by Minimum Stent Length
Figure 4.6 Cardiovascular Drug Eluting Stents: Distribution by Maximum Stent Diameter
Figure 4.7 Cardiovascular Drug Eluting Stents: Distribution by Minimum Stent Diameter
Figure 4.8 Cardiovascular Drug Eluting Stents: Distribution by Maximum Nominal Pressure
Figure 4.9 Cardiovascular Drug Eluting Stents: Distribution by Maximum Rated Burst Pressure
Figure 4.10 Cardiovascular Drug Eluting Stents: Distribution by Administered Drug Concentration
Figure 4.11 Cardiovascular Drug Eluting Stents: Distribution by Minimum Strut Thickness
Figure 4.12 Cardiovascular Drug Eluting Stents Developers: Distribution by Year of Establishment
Figure 4.13 Cardiovascular Drug Eluting Stents Developers: Distribution by Company Size
Figure 4.14 Cardiovascular Drug Eluting Stents Developers: Distribution by Location of Headquarters
Figure 4.15 Leading Players: Distribution by Number of Products
Figure 5.1 Key Insights: Distribution by Type of Drug Eluted and Administered Drug Concentration
Figure 5.2 Key Insights: Distribution by Type of Drug Eluted and Stent Material
Figure 5.3 Key Insights: Distribution by Maximum Stent Length and Maximum Stent Diameter
Figure 5.4 Key Insights: Distribution by Year of Establishment, Company Size, Number of Products Offered and Location of Headquarters
Figure 5.5 Key Insights: Distribution by Company Size, Number of Products Offered, Maximum Stent Length, Maximum Stent Diameter and Location of Headquarters
Figure 6.1 Company Competitiveness Analysis: Small Companies
Figure 6.2 Company Competitiveness Analysis: Mid-sized Companies
Figure 6.3 Company Competitiveness Analysis: Large Companies
Figure 6.4 Company Competitiveness Analysis: Very Large Companies
Figure 8.1 Patent Analysis: Distribution by Type of Patent
Figure 8.2 Patent Analysis: Cumulative Distribution by Publication Year, 2012-2022
Figure 8.3 Patent Analysis: Cumulative Distribution of Granted Patents by Publication Year, 2012-2021
Figure 8.4 Patent Analysis: Cumulative Distribution of Filed Patents by Publication Year, 2012-2022
Figure 8.5 Patent Analysis: Cumulative Distribution of Patents by Publication Year and Type of Player, 2012-2022
Figure 8.6 Patent Analysis: Distribution by Issuing Authority
Figure 8.7 Patent Analysis: Distribution by Patent Focus
Figure 8.8 Patent Analysis: Distribution by Patent Age
Figure 8.9 Patent Analysis: Distribution by CPC Symbols
Figure 8.10 Leading Industry Players: Distribution by Number of Patents
Figure 8.11 Leading Non-Industry Players: Distribution by Number of Patents
Figure 8.12 Leading Inventors: Distribution by Number of Patents
Figure 8.13 Patent Analysis (Top 10 CPC Symbols): Benchmarking by Leading Players
Figure 8.14 Patent Analysis (Leading Players): Benchmarking by Top 10 CPC Symbols
Figure 8.15 Patent Analysis: Valuation Analysis
Figure 9.1 Novel Cardiovascular Therapeutic Developers: Distribution by Year of Establishment
Figure 9.2 Novel Cardiovascular Therapeutics Developers: Distribution by Company Size
Figure 9.3 Novel Cardiovascular Therapeutics Developers: Distribution by Location of Headquarters
Figure 9.4 Novel Cardiovascular Therapeutics: Distribution by Type of Therapy
Figure 9.5 Novel Cardiovascular Therapeutics: Distribution by Phase of Development
Figure 9.6 Gene Therapy: Distribution by Phase of Development
Figure 9.7 Gene Therapy: Distribution by Route of Administration
Figure 9.8 Gene Therapy: Distribution by Type of Vector Used
Figure 9.9 Gene Therapy: Distribution by Type of Gene / Molecule Used
Figure 9.10 Gene Therapy: Distribution by Type of Vector Used and Therapeutic Approach
Figure 9.11 Subcutaneous Biologics: Distribution by Phase of Development
Figure 9.12 Subcutaneous Biologics: Distribution by Type of Molecule
Figure 9.13 Subcutaneous Biologics: Distribution by Phase of Development and Type of Molecule
Figure 9.14 Subcutaneous Biologics: Distribution by Mechanism of Action
Figure 9.15 Novel Cardiovascular-based Services / Solutions Providers: Distribution by Year of Establishment
Figure 9.16 Novel Cardiovascular-based Services / Solutions Providers: Distribution by Company Size
Figure 9.17 Novel Cardiovascular-based Services / Solutions Providers: Distribution by Location of Headquarters
Figure 9.18 Novel Cardiovascular-based Services / Solutions: Distribution by Type of Service
Figure 9.19 Biopharmaceutical Contract Research Service Providers: Distribution by Scale of Operation
Figure 9.20 Biopharmaceutical Contract Research Service Providers: Distribution by Type of Biologic
Figure 9.21 Biopharmaceutical Contract Research Service Providers: Distribution by Type of Preclinical Services Offered
Figure 9.22 Biopharmaceutical Contract Research Service Providers: Distribution by Type of Clinical Service Offered
Figure 9.23 Biopharmaceutical Contract Research Service Providers: Type of Biologics and Type of Preclinical Services Offered
Figure 9.24 Biopharmaceutical Contract Research Service Providers: Type of Biologic and Type of Clinical Service Offered
Figure 9.25 Digital Therapeutics Solutions: Distribution by Status of Development
Figure 9.26 Digital Therapeutics Solutions: Distribution by Type of Solution
Figure 9.27 Digital Therapeutics Solution: Distribution by Type of Therapy
Figure 9.28 Digital Therapeutics Solutions: Distribution by Purpose of Solution
Figure 9.29 Digital Therapeutics Solutions: Distribution by Type of Therapy and Purpose of Solution
Figure 9.30 Digital Therapeutics Solutions: Distribution by Target Population
Figure 9.31 Digital Therapeutics Solutions: Distribution by Duration of Treatment
Figure 9.32 Digital Therapeutics Solution: Distribution by Prescription Requirement
Figure 9.33 Precision Medicine Software: Distribution by End-user
Figure 9.34 Precision Medicine Software: Distribution by Purpose of Software
Figure 9.35 Precision Medicine Software: Distribution by Type of Data Handled
Figure 9.36 Precision Medicine Software: Distribution by Market Status
Figure 9.37 Precision Medicine Software: Distribution by Type of Data Handled and Status of Software
Figure 10.1 Global Demand for Cardiovascular Drug Eluting Stents, 2022-2035 (Million Units)
Figure 10.2 Global Demand for Cardiovascular Drug Eluting Stents: Distribution by Type of Drug Eluted, 2022 and 2035
Figure 10.3 Global Demand for Sirolimus Eluting Stents, 2022-2035 (Million Units)
Figure 10.4 Global Demand for Paclitaxel Eluting Stents, 2022-2035 (Million Units)
Figure 10.5 Global Demand for Everolimus Eluting Stents, 2022-2035 (Million Units)
Figure 10.6 Global Demand for Zotarolimus Eluting Stents, 2022-2035 (Million Units)
Figure 10.7 Global Demand for Other Drug Eluting Stents, 2022-2035 (Million Units)
Figure 10.8 Global Demand for Cardiovascular Drug Eluting Stents: Distribution by Stent Material, 2022 and 2035
Figure 10.9 Global Demand for Platinum Chromium Stents, 2022-2035 (Million Units)
Figure 10.10 Global Demand for Cobalt Alloy Stents, 2022-2035 (Million Units)
Figure 10.11 Global Demand for Stainless Steel Stents, 2022-2035 (Million Units)
Figure 10.12 Global Demand for Stents Based on Other Materials, 2022-2035 (Million Units)
Figure 10.13 Global Demand for Cardiovascular Drug Eluting Stents: Distribution by Geography, 2022 and 2035
Figure 10.14 Demand for Cardiovascular Drug Eluting Stents in North America, 2022-2035 (Million Units)
Figure 10.15 Demand for Cardiovascular Drug Eluting Stents in the US, 2022-2035 (Million Units)
Figure 10.16 Demand for Cardiovascular Drug Eluting Stents in Canada, 2022-2035 (Million Units)
Figure 10.17 Demand for Cardiovascular Drug Eluting Stents in Europe, 2022-2035 (Million Units)
Figure 10.18 Demand for Cardiovascular Drug Eluting Stents in France, 2022-2035 (Million Units)
Figure 10.19 Demand for Cardiovascular Drug Eluting Stents in Germany, 2022-2035 (Million Units)
Figure 10.20 Demand for Cardiovascular Drug Eluting Stents in Italy, 2022-2035 (Million Units)
Figure 10.21 Demand for Cardiovascular Drug Eluting Stents in the Netherlands, 2022-2035 (Million Units)
Figure 10.22 Demand for Cardiovascular Drug Eluting Stents in Spain, 2022-2035 (Million Units)
Figure 10.23 Demand for Cardiovascular Drug Eluting Stents in the UK, 2022-2035 (Million Units)
Figure 10.24 Demand for Cardiovascular Drug Eluting Stents in Asia, 2022-2035 (Million Units)
Figure 10.25 Demand for Cardiovascular Drug Eluting Stents in China, 2022-2035 (Million Units)
Figure 10.26 Demand for Cardiovascular Drug Eluting Stents in India, 2022-2035 (Million Units)
Figure 10.27 Demand for Cardiovascular Drug Eluting Stents in Japan, 2022-2035 (Million Units)
Figure 10.28 Demand for Cardiovascular Drug Eluting Stents in South Korea, 2022-2035 (Million Units)
Figure 10.29 Demand for Cardiovascular Drug Eluting Stents in Middle East and North Africa, 2022-2035 (Million Units)
Figure 10.30 Demand for Cardiovascular Drug Eluting Stents in Israel, 2022-2035 (Million Units)
Figure 10.31 Demand for Cardiovascular Drug Eluting Stents in Turkey, 2022-2035 (Million Units)
Figure 10.32 Demand for Cardiovascular Drug Eluting Stents in Latin America, 2022-2035 (Million Units)
Figure 10.33 Demand for Cardiovascular Drug Eluting Stents in Brazil, 2022-2035 (Million Units)
Figure 10.34 Demand for Cardiovascular Drug Eluting Stents in Rest of the World, 2022-2035 (Million Units)
Figure 10.35 Demand for Cardiovascular Drug Eluting Stents in Australia, 2022-2035 (Million Units)
Figure 10.36 Demand for Cardiovascular Drug Eluting Stents in New Zealand, 2022-2035 (Million Units)
Figure 11.1 Global Novel Cardiovascular Drug Delivery Devices Market, 2022-2035 (USD Million)
Figure 11.2 Global Novel Cardiovascular Drug Delivery Devices Market: Distribution by Type of Drug Eluted, 2022 and 2035
Figure 11.3 Global Sirolimus Eluting Stents Market, 2022-2035 (USD Million)
Figure 11.4 Global Paclitaxel Eluting Stents Market, 2022-2035 (USD Million)
Figure 11.5 Global Everolimus Eluting Stents Market, 2022-2035 (USD Million)
Figure 11.6 Global Zotarolimus Eluting Stents Market, 2022-2035 (USD Million)
Figure 11.7 Global Other Drug Eluting Stents Market, 2022-2035 (USD Million)
Figure 11.8 Global Novel Cardiovascular Drug Delivery Devices Market: Distribution by Stent Material, 2022 and 2035
Figure 11.9 Global Platinum Chromium Stents Market, 2022-2035 (USD Million)
Figure 11.10 Global Cobalt Alloy Stents Market, 2022-2035 (USD Million)
Figure 11.11 Global Stainless Steel Stents Market, 2022-2035 (USD Million)
Figure 11.12 Global Market for Stents Based on Other Materials, 2022-2035 (USD Million)
Figure 11.13 Global Novel Cardiovascular Drug Delivery Devices Market: Distribution by Geography, 2022 and 2035
Figure 11.14 Novel Cardiovascular Drug Delivery Devices Market in North America, 2022-2035 (USD Million)
Figure 11.15 Novel Cardiovascular Drug Delivery Devices Market in the US, 2022-2035 (USD Million)
Figure 11.16 Novel Cardiovascular Drug Delivery Devices Market in Canada, 2022-2035 (USD Million)
Figure 11.17 Novel Cardiovascular Drug Delivery Devices Market in Europe, 2022-2035 (USD Million)
Figure 11.18 Novel Cardiovascular Drug Delivery Devices Market in France, 2022-2035 (USD Million)
Figure 11.19 Novel Cardiovascular Drug Delivery Devices Market in Germany, 2022-2035 (USD Million)
Figure 11.20 Novel Cardiovascular Drug Delivery Devices Market in Italy, 2022-2035 (USD Million)
Figure 11.21 Novel Cardiovascular Drug Delivery Devices Market in the Netherlands, 2022-2035 (USD Million)
Figure 11.22 Novel Cardiovascular Drug Delivery Devices Market in Spain, 2022-2035 (USD Million)
Figure 11.23 Novel Cardiovascular Drug Delivery Devices Market in the UK, 2022-2035 (USD Million)
Figure 11.24 Novel Cardiovascular Drug Delivery Devices Market in Asia, 2022-2035 (USD Million)
Figure 11.25 Novel Cardiovascular Drug Delivery Devices Market in China, 2022-2035 (USD Million)
Figure 11.26 Novel Cardiovascular Drug Delivery Devices Market in India, 2022-2035 (USD Million)
Figure 11.27 Novel Cardiovascular Drug Delivery Devices Market in Japan, 2022-2035 (USD Million)
Figure 11.28 Novel Cardiovascular Drug Delivery Devices Market in South Korea, 2022-2035 (USD Million)
Figure 11.29 Novel Cardiovascular Drug Delivery Devices Market in Middle East and North Africa, 2022-2035 (USD Million)
Figure 11.30 Novel Cardiovascular Drug Delivery Devices Market in Israel, 2022-2035 (USD Million)
Figure 11.31 Novel Cardiovascular Drug Delivery Devices Market in Turkey, 2022-2035 (USD Million)
Figure 11.32 Novel Cardiovascular Drug Delivery Devices Market in Latin America, 2022-2035 (USD Million)
Figure 11.33 Novel Cardiovascular Drug Delivery Devices Market in Brazil, 2022-2035 (USD Million)
Figure 11.34 Novel Cardiovascular Drug Delivery Devices Market in Rest of the World, 2022-2035 (USD Million)
Figure 11.35 Novel Cardiovascular Drug Delivery Devices Market in Australia, 2022-2035 (USD Million)
Figure 11.36 Novel Cardiovascular Drug Delivery Devices Market in New Zealand, 2022-2035 (USD Million)
Figure 12.1 Concluding Remarks: Current Market Landscape
Figure 12.2 Concluding Remarks: Patent Analysis
Figure 12.3 Concluding Remarks: Demand Analysis
Figure 12.4 Concluding Remarks: Market Forecast

List Of Tables

Table 4.1 Cardiovascular Drug Eluting Stents: Information on Type of Drug Eluted
Table 4.2 Cardiovascular Drug Eluting Stents: Information on Stent Material
Table 4.3 Cardiovascular Drug Eluting Stents: Information on Maximum Post Dilatation Limit
Table 4.4 Cardiovascular Drug Eluting Stents: Information on Maximum and Minimum Stent Length
Table 4.5 Cardiovascular Drug Eluting Stents: Information on Maximum and Minimum Stent Diameter
Table 4.6 Cardiovascular Drug Eluting Stents: Information on Maximum Nominal Pressure
Table 4.7 Cardiovascular Drug Eluting Stents: Information on Maximum Rated Burst Pressure
Table 4.8 Cardiovascular Drug Eluting Stents: Information on Administered Drug Concentration
Table 4.9 Cardiovascular Drug Eluting Stents: Information on Minimum Strut Thickness
Table 4.10 Cardiovascular Drug Eluting Stent Providers: Information on Year of Establishment, Company Size, Location of Headquarters, Region of Headquarters and Number of Products
Table 5.1 Company Competitiveness Analysis: List of Small Players
Table 5.2 Company Competitiveness Analysis: List of Mid-sized Players
Table 5.3 Company Competitiveness Analysis: List of Large Players
Table 5.4 Company Competitiveness Analysis: List of Very Large Players
Table 7.1 List of Companies Profiled
Table 7.2 Alvimedica: Company Overview
Table 7.3 Alvimedica: Cardiovascular Drug Delivery Device Portfolio
Table 7.3 Alvimedica: Recent Developments and Future Outlook
Table 7.4 B. Braun: Company Overview
Table 7.5 B. Braun: Cardiovascular Drug Delivery Device Portfolio
Table 7.6 B. Braun: Recent Developments and Future Outlook
Table 7.7 Boston Scientific: Company Overview
Table 7.8 Boston Scientific: Cardiovascular Drug Delivery Device Portfolio
Table 7.9 Boston Scientific: Recent Developments and Future Outlook
Table 7.10 Cook Medical: Company Overview
Table 7.11 Cook Medical: Cardiovascular Drug Delivery Device Portfolio
Table 7.12 Cook Medical: Recent Developments and Future Outlook
Table 7.13 Endocor: Company Overview
Table 7.14 Endocor: Cardiovascular Drug Delivery Device Portfolio
Table 7.15 Endocor: Recent Developments and Future Outlook
Table 7.16 Eurocor: Company Overview
Table 7.17 Eurocor: Cardiovascular Drug Delivery Device Portfolio
Table 7.18 Eurocor: Recent Developments and Future Outlook
Table 7.19 iVascular: Company Overview
Table 7.20 iVascular: Cardiovascular Drug Delivery Device Portfolio
Table 7.21 iVascular: Recent Developments and Future Outlook
Table 7.22 Lepu Medical: Company Overview
Table 7.23 Lepu Medical: Cardiovascular Drug Delivery Device Portfolio
Table 7.24 Lepu Medical: Recent Developments and Future Outlook
Table 7.25 Medinol: Company Overview
Table 7.26 Medinol: Cardiovascular Drug Delivery Device Portfolio
Table 7.27 Medinol: Recent Developments and Future Outlook
Table 7.28 Medtronic: Company Overview
Table 7.29 Medtronic: Cardiovascular Drug Delivery Device Portfolio
Table 7.30 Medtronic: Recent Developments and Future Outlook
Table 7.31 Meril: Company Overview
Table 7.32 Meril: Cardiovascular Drug Delivery Device Portfolio
Table 7.33 Meril: Recent Developments and Future Outlook
Table 7.34 Relisys Medical Devices: Company Overview
Table 7.35 Relisys Medical Devices: Cardiovascular Drug Delivery Device Portfolio
Table 7.36 Relisys Medical Devices: Recent Developments and Future Outlook
Table 7.37 Sahajanand Medical Technologies: Company Overview
Table 7.38 Sahajanand Medical Technologies: Cardiovascular Drug Delivery Device Portfolio
Table 7.39 Sahajanand Medical Technologies: Recent Developments and Future Outlook
Table 7.40 Sinomed: Company Overview
Table 7.41 Sinomed: Cardiovascular Drug Delivery Device Portfolio
Table 7.42 Sinomed: Recent Developments and Future Outlook
Table 7.43 Vascular Concepts: Company Overview
Table 7.44 Vascular Concepts: Cardiovascular Drug Delivery Device Portfolio
Table 7.45 Vascular Concepts: Recent Developments and Future Outlook
Table 8.1 Patent Analysis: CPC Symbols
Table 8.2 Patent Analysis: Most Popular CPC Symbols
Table 8.3 Patent Analysis: List of Top 10 CPC Symbols
Table 8.4 Patent Portfolio: Summary of Benchmarking Analysis
Table 8.5 Patent Analysis: Categorization Based on Weighted Valuation Score
Table 8.6 Patent Analysis: List of Relatively Higher Value Patents
Table 13.1 Scitech Medical: Company Snapshot
Table 13.2 Translumina: Company Snapshot
Table 14.1 Cardiovascular Drug Eluting Stents: Distribution by Type of Drug Eluted
Table 14.2 Cardiovascular Drug Eluting Stents: Distribution by Stent Material
Table 14.3 Cardiovascular Drug Eluting Stents: Distribution by Maximum Post Dilatation Limit
Table 14.4 Cardiovascular Drug Eluting Stents: Distribution by Maximum Stent Length
Table 14.5 Cardiovascular Drug Eluting Stents: Distribution by Minimum Stent Length
Table 14.6 Cardiovascular Drug Eluting Stents: Distribution by Maximum Stent Diameter
Table 14.7 Cardiovascular Drug Eluting Stents: Distribution by Minimum Stent Diameter
Table 14.8 Cardiovascular Drug Eluting Stents: Distribution by Maximum Nominal Pressure
Table 14.9 Cardiovascular Drug Eluting Stents: Distribution by Maximum Rated Burst Pressure
Table 14.10 Cardiovascular Drug Eluting Stents: Distribution by Administered Drug Concentration
Table 14.11 Cardiovascular Drug Eluting Stents: Distribution by Minimum Strut Thickness
Table 14.12 Cardiovascular Drug Eluting Stents Developers: Distribution by Year of Establishment
Table 14.13 Cardiovascular Drug Eluting Stents Developers: Distribution by Company Size
Table 14.14 Cardiovascular Drug Eluting Stents Developers: Distribution by Location of Headquarters
Table 14.15 Leading Players: Distribution by Number of Products
Table 14.16 Key Insights: Distribution by Type of Drug Eluted and Administered Drug Concentration
Table 14.17 Key Insights: Distribution by Type of Drug Eluted and Stent Material
Table 14.18 Key Insights: Distribution by Maximum Stent Length and Maximum Stent Diameter
Table 14.19 Key Insights: Distribution by Year of Establishment, Company Size, Number of Products Offered and Location of Headquarters
Table 14.20 Key Insights: Distribution by Company Size, Number of Products Offered, Maximum Stent Length, Maximum Stent Diameter and Location of Headquarters
Table 14.21 Patent Analysis: Distribution by Type of Patent
Table 14.22 Patent Analysis: Cumulative Distribution by Publication Year, 2012-2022
Table 14.23 Patent Analysis: Cumulative Distribution of Granted Patents by Publication Year, 2012-2021
Table 14.24 Patent Analysis: Cumulative Distribution of Filed Patents by Publication Year, 2012-2022
Table 14.25 Patent Analysis: Cumulative Distribution of Patents by Publication Year and Type of Player, 2012-2022
Table 14.26 Patent Analysis: Distribution by Issuing Authority
Table 14.27 Patent Analysis: Distribution by Patent Age
Table 14.28 Leading Players: Distribution by Number of Patents
Table 14.29 Leading Non-industry Players: Distribution by Number of Patents
Table 14.30 Leading Inventors: Distribution by Number of Patents
Table 14.31 Novel Cardiovascular Therapeutics Developers: Distribution by Year of Establishment
Table 14.32 Novel Cardiovascular Therapeutics Developers: Distribution by Company Size
Table 14.33 Novel Cardiovascular Therapeutics Developers: Distribution by Location of Headquarters
Table 14.34 Novel Cardiovascular Therapeutics: Distribution by Type of Therapy
Table 14.35 Novel Cardiovascular Therapeutics: Distribution by Phase of Development
Table 14.36 Gene Therapy: Distribution by Phase of Development
Table 14.37 Gene Therapy: Distribution by Route of Administration
Table 14.38 Gene Therapy: Distribution by Type of Vector Used
Table 14.39 Gene Therapy: Distribution by Type of Gene / Molecule Used
Table 14.40 Gene Therapy: Distribution by Type of Vector Used and Therapeutic Approach
Table 14.41 Subcutaneous Biologics: Distribution by Phase of Development
Table 14.42 Subcutaneous Biologics: Distribution by Type of Molecules
Table 14.43 Subcutaneous Biologics: Distribution by Phase of Development and Type of Molecule
Table 14.44 Subcutaneous Biologics: Distribution by Mechanism of Action
Table 14.45 Novel Cardiovascular-based Service Providers: Distribution by Year of Establishment
Table 14.46 Novel Cardiovascular-based Service Providers: Distribution by Company Size
Table 14.47 Novel Cardiovascular-based Service Providers: Distribution by Location of Headquarters
Table 14.48 Novel Cardiovascular-based Services: Distribution by Type of Service
Table 14.49 Biopharmaceutical Contract Research Service Providers: Distribution by Scale of Operation
Table 14.50 Biopharmaceutical Contract Research Service Providers: Distribution by Type of Biologic
Table 14.51 Biopharmaceutical Contract Research Service Providers: Distribution by Type of Preclinical Services Offered
Table 14.52 Biopharmaceutical Contract Research Service Providers: Distribution by Type of Clinical Services Offered
Table 14.53 Biopharmaceutical Contract Research Service Providers: Type of Biologics and Type of Preclinical Services Offered
Table 14.54 Biopharmaceutical Contract Research Service Providers: Type of Biologics and Type of Clinical Services Offered
Table 14.55 Digital Therapeutics Solutions: Distribution by Status of Development
Table 14.56 Digital Therapeutics Solutions: Distribution by Type of Solution
Table 14.57 Digital Therapeutics Solutions: Distribution by Type of Therapy
Table 14.58 Digital Therapeutics Solutions: Distribution by Purpose of Solution
Table 14.59 Digital Therapeutics Solutions: Distribution by Type of Therapy and Purpose of Solution
Table 14.60 Digital Therapeutics Solutions: Distribution by Target Population
Table 14.61 Digital Therapeutics Solutions: Distribution by Duration of Treatment
Table 14.62 Digital Therapeutics Solutions: Distribution by Prescription Requirement
Table 14.63 Precision Medicine Software: Distribution by Type of End User
Table 14.64 Precision Medicine Software: Distribution by Purpose of Software
Table 14.65 Precision Medicine Software: Distribution by Type of Data Handled
Table 14.66 Precision Medicine Software: Distribution by Market Status
Table 14.67 Precision Medicine Software: Distribution by Type of Data Handled and Status of Software
Table 14.68 Global Demand for Cardiovascular Drug Eluting Stents, 2022-2035 (Million Units)
Table 14.69 Global Demand for Cardiovascular Drug Eluting Stents: Distribution by Type of Drug Eluted, 2022 and 2035
Table 14.70 Global Demand for Sirolimus Eluting Stents, 2022-2035 (Million Units)
Table 14.71 Global Demand for Paclitaxel Eluting Stents, 2022-2035 (Million Units)
Table 14.72 Global Demand for Everolimus Eluting Stents, 2022-2035 (Million Units)
Table 14.73 Global Demand for Zotarolimus Eluting Stents, 2022-2035 (Million Units)
Table 14.74 Global Demand for Other Drug Eluting Stents, 2022-2035 (Million Units)
Table 14.75 Global Demand for Cardiovascular Drug Eluting Stents: Distribution by Stent Material, 2022 and 2035
Table 14.76 Global Demand for Platinum Chromium Stents, 2022-2035 (Million Units)
Table 14.77 Global Demand for Cobalt Alloy Stents, 2022-2035 (Million Units)
Table 14.78 Global Demand for Stainless Steel Stents, 2022-2035 (Million Units)
Table 14.79 Global Demand for Stents Based on Other Materials, 2022-2035 (Million Units)
Table 14.80 Global Demand for Cardiovascular Drug Eluting Stents: Distribution by Geography, 2022 and 2035
Table 14.81 Demand for Cardiovascular Drug Eluting Stents in North America, 2022-2035 (Million Units)
Table 14.82 Demand for Cardiovascular Drug Eluting Stents in the US, 2022-2035 (Million Units)
Table 14.83 Demand for Cardiovascular Drug Eluting Stents in Canada, 2022-2035 (Million Units)
Table 14.84 Demand for Cardiovascular Drug Eluting Stents in Europe, 2022-2035 (Million Units)
Table 14.85 Demand for Cardiovascular Drug Eluting Stents in France, 2022-2035 (Million Units)
Table 14.86 Demand for Cardiovascular Drug Eluting Stents in Germany, 2022-2035 (Million Units)
Table 14.87 Demand for Cardiovascular Drug Eluting Stents in Italy, 2022-2035 (Million Units)
Table 14.88 Demand for Cardiovascular Drug Eluting Stents in the Netherlands, 2022-2035 (Million Units)
Table 14.89 Demand for Cardiovascular Drug Eluting Stents in Spain, 2022-2035 (Million Units)
Table 14.90 Demand for Cardiovascular Drug Eluting Stents in the UK, 2022-2035 (Million Units)
Table 14.91 Demand for Cardiovascular Drug Eluting Stents in Asia, 2022-2035 (Million Units)
Table 14.92 Demand for Cardiovascular Drug Eluting Stents in China, 2022-2035 (Million Units)
Table 14.93 Demand for Cardiovascular Drug Eluting Stents in India, 2022-2035 (Million Units)
Table 14.94 Demand for Cardiovascular Drug Eluting Stents in Japan, 2022-2035 (Million Units)
Table 14.95 Demand for Cardiovascular Drug Eluting Stents in South Korea, 2022-2035 (Million Units)
Table 14.96 Demand for Cardiovascular Drug Eluting Stents in Middle East and North Africa, 2022-2035 (Million Units)
Table 14.97 Demand for Cardiovascular Drug Eluting Stents in Israel, 2022-2035 (Million Units)
Table 14.98 Demand for Cardiovascular Drug Eluting Stents in Turkey, 2022-2035 (Million Units)
Table 14.99 Demand for Cardiovascular Drug Eluting Stents in Latin America, 2022-2035 (Million Units)
Table 14.100 Demand for Cardiovascular Drug Eluting Stents in Brazil, 2022-2035 (Million Units)
Table 14.101 Demand for Cardiovascular Drug Eluting Stents in Rest of the World, 2022-2035 (Million Units)
Table 14.102 Demand for Cardiovascular Drug Eluting Stents in Australia, 2022-2035 (Million Units)
Table 14.103 Demand for Cardiovascular Drug Eluting Stents in New Zealand, 2022-2035 (Million Units)
Table 14.104 Global Novel Cardiovascular Drug Delivery Devices Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.105 Global Novel Cardiovascular Drug Delivery Devices Market: Distribution by Type of Drug Eluted, 2022 and 2035
Table 14.106 Global Sirolimus Eluting Stents Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.107 Global Paclitaxel Eluting Stents Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.108 Global Everolimus Eluting Stents Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.109 Global Zotarolimus Eluting Stents Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.110 Global Other Drug Eluting Stents Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.111 Global Novel Cardiovascular Drug Delivery Devices Market: Distribution by Stent Material, 2022 and 2035
Table 14.112 Global Platinum Chromium Stents Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.113 Global Cobalt Alloy Stents Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.114 Global Stainless Steel Stents Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.115 Global Market for Stents Based on Other Materials, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.116 Global Novel Cardiovascular Drug Delivery Devices Market: Distribution by Geography, 2022 and 2035
Table 14.117 Novel Cardiovascular Drug Delivery Devices Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.118 Novel Cardiovascular Drug Delivery Devices Market in the US, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.119 Novel Cardiovascular Drug Delivery Devices Market in Canada, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.120 Novel Cardiovascular Drug Delivery Devices Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.121 Novel Cardiovascular Drug Delivery Devices Market in France, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.122 Novel Cardiovascular Drug Delivery Devices Market in Germany, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.123 Novel Cardiovascular Drug Delivery Devices Market in Italy, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.124 Novel Cardiovascular Drug Delivery Devices Market in the Netherlands, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.125 Novel Cardiovascular Drug Delivery Devices Market in Spain, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.126 Novel Cardiovascular Drug Delivery Devices Market in the UK, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.127 Novel Cardiovascular Drug Delivery Devices Market in Asia, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.128 Novel Cardiovascular Drug Delivery Devices Market in China, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.129 Novel Cardiovascular Drug Delivery Devices Market in India, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.130 Novel Cardiovascular Drug Delivery Devices Market in Japan, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.131 Novel Cardiovascular Drug Delivery Devices Market in South Korea, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.132 Novel Cardiovascular Drug Delivery Devices Market in Middle East and North Africa, 2022-2035 (USD Million)
Table 14.133 Novel Cardiovascular Drug Delivery Devices Market in Israel, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.134 Novel Cardiovascular Drug Delivery Devices Market in Turkey, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.135 Novel Cardiovascular Drug Delivery Devices Market in Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.136 Novel Cardiovascular Drug Delivery Devices Market in Brazil, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.137 Novel Cardiovascular Drug Delivery Devices Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.138 Novel Cardiovascular Drug Delivery Devices Market in Australia, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 14.139 Novel Cardiovascular Drug Delivery Devices Market in New Zealand, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. AaviGen
  2. Abbott
  3. Abiogenesis Clinpharm
  4. Acceleron (Acquired by Merck)
  5. Accura Medizintechnik
  6. Aesculap (Acquired by B. Braun)
  7. Aesculape CRO 
  8. Alexion
  9. Alnylam
  10. Alvimedica
  11. Ambulero
  12. American Heart Association
  13. amg International
  14. Amgen
  15. Amsino
  16. Anaeropharma Science
  17. AnGes
  18. Angionetics
  19. Anlong Bio
  20. Asklepios BioPharmaceutical
  21. Astellas 
  22. AstraZeneca
  23. B. Braun
  24. Balton
  25. BioMarin
  26. Biosensors International
  27. BIOTRONIK
  28. Boston Scientific
  29. Breakthrough Genomics
  30. Bristol Myers Squibb
  31. California Institute of Technology
  32. Cambridge University Hospitals NHS Foundation Trust
  33. Cardionovum
  34. CiVi Biopharma
  35. Cohesic
  36. Consip
  37. Cook Medical
  38. Corvidia Therapeutics
  39. DiNAQOR
  40. Dyno Therapeutics
  41. Eli Lilly
  42. Elixir Medical
  43. ENDOCOR
  44. Eucatech
  45. Eurocor
  46. Excelya
  47. Genedata
  48. Genelife Clinical Research
  49. Genoss
  50. Helixmith
  51. HP
  52. Huapont Life Sciences
  53. Human Longevity
  54. Human Stem Cells Institute
  55. Hygea Precision Medicine 
  56. Infraredx
  57. Innovent Biologics
  58. InSitu Technologies
  59. Integer
  60. Ionis Pharmaceuticals
  61. iVascular
  62. Jiangsu Hengrui Medicine
  63. Johnson & Johnson
  64. Lepu Medical
  65. LEXEO Therapeutics
  66. Liaoning Yinyi Biological Technology
  67. LIB Therapeutics
  68. LifeOmic
  69. Medinol
  70. Medipredict
  71. Medtronic
  72. Meril 
  73. Metabolon
  74. MicroPort
  75. Minvasys
  76. Mitsubishi Tanabe Pharma
  77. Multimedics
  78. Nuevocor
  79. Novartis
  80. N-ovative Health Technologies
  81. Numed Technologies
  82. Oracle
  83. Perceiv AI
  84. Pharming
  85. PhaseBio
  86. Precigen
  87. QAscent Research Solutions
  88. QualiMed
  89. Regeneron
  90. Relisys Medical Devices
  91. Renalytix
  92. Renova Therapeutics
  93. REVA Medical
  94. REYON Pharmaceuticals
  95. Rontis
  96. R-Pharm
  97. S3V Vascular Technologies
  98. Sahajanand Laser Technology
  99. Sahajanand Medical Technologies
  100. SalioGen Therapeutics
  101. Sarepta Therapeutics
  102. SCITECH Medical
  103. Siguler Guff
  104. SINOMED
  105. Skyline Therapeutics
  106. SOPHiA GENETICS
  107. Steel Partners
  108. Strand Life Sciences
  109. StrideBio
  110. Tenaya Therapeutics
  111. Terumo
  112. Translumina
  113. uniQure
  114. University of Florida
  115. USM Healthcare
  116. Vascular Concepts (Acquired by Sahajanand Medical Technologies)
  117. VBL Therapeutics
  118. Verily
  119. XBiotech
  120. Xcene Research
  121. XyloCor Therapeutics
  122. Zarek Distribuidora De Produtos Hospitalares (Acquired by Sahajanand Medical Technologies)
  123. Zensun

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com